From Stripping to Light: The Global Shift to Endovenous Ablation for Varicose Veins

Act I — The burden and the market

Takeaway: the addressable population is vast, aging, getting heavier, and under-treated — a large latent demand pool, not a saturated market.

A disease that dwarfs the conditions it is compared to

Chronic venous disease (CVD) is one of the most prevalent and least-discussed conditions in vascular medicine. In the United States alone, roughly 190 million adults are estimated to live with some form of CVD — a figure that dwarfs diabetes (38M), peripheral artery disease (22M) and all cancers combined (18M), and which has been characterised as "underestimated, underdiagnosed and undertreated"¹. More than 40 million Americans have varicose veins specifically, with prevalence skewing female (roughly 55% women versus 45% men) and rising steeply with age².

Beneath the headline prevalence sits a severity pyramid. Of the affected population, an estimated 25 million US adults have chronic venous insufficiency (CVI), around 6 million have advanced disease, and roughly 500,000 carry active venous ulcers⁵. StatPearls puts CVI prevalence at 10%–35% of US adults and notes that CVI management already consumes about 2% of total US healthcare spending⁶. The global picture is, if anything, larger: the geographically diverse Vein Consult Program reported a worldwide CVD prevalence of 83.6% (63.9% in classes C1–C6 and 19.7% with C0s telangiectasia), at a mean age of 50.6 years⁷.

Prevalence estimates vary widely by definition and geography — varicose-vein prevalence has been reported anywhere from 2%–56% in men and 1%–60% in women⁸ — so the precise denominator is contested. What is not contested is the order of magnitude: tens of millions of affected adults in the US and hundreds of millions globally.

Under-treated, not over-served

The clinical literature consistently describes CVI as "a frequently underdiagnosed and undertreated pathology"⁹. Clinic-marketing sources put the treatment gap more starkly — claiming fewer than one-half of one percent of Americans seek treatment, and that fewer than half a million ever receive it¹⁰ — but that specific figure is not peer-reviewed and should be read as directional, not definitive. The robust, defensible version of the claim rests on prevalence and qualitative consensus: a population in the tens of millions, a treated cohort an order of magnitude smaller, and authoritative sources calling the condition under-diagnosed. The latent demand pool is large by any reasonable reading.

Demographics are a durable secular tailwind

Two structural drivers — age and obesity — are expected to push procedural demand higher for decades. The longitudinal Edinburgh Vein Study, the strongest evidence base here, found annual varicose-vein incidence of 2.6% in women and 1.9% in men, and a 13-year cumulative incidence that climbs from 9.8% (ages 18–34) to 25.7% (ages 55–64) — incidence nearly triples across the working-age span¹¹. Disease also progresses once present: 57.8% of CVD patients progressed over 13 years (~4.3%/year), about a third of those with varicose veins alone went on to develop CVI, and overweight carried an odds ratio of 1.85¹².

Obesity compounds the trend. US adult obesity now sits at roughly 42% (CDC), cited directly as a driver of rising CVI and procedural demand¹³; overweight women carry roughly 50% higher varicose-vein risk and those with BMI over 30 around triple the risk, with prevalence in older women reported as high as ~40% in clinic-source data². An aging, increasingly obese population is, in effect, a demand-compounding machine.

The market: every forecaster agrees on direction

Translate that epidemiology into device dollars and the analyst community converges on a clear signal. Across roughly a dozen independent publishers, the varicose-vein treatment-device market sits at about USD 1.4–1.6 billion today and grows at a 5.5%–9.0% CAGR through the early 2030s. DelveInsight sizes it at USD 1.61B (2024) rising to USD 2.60B (2032) at 6.25%; Fortune Business Insights at USD 1.62B (2025) to USD 3.17B (2034) at 7.72%; Coherent Market Insights at USD 1.46B (2026) to USD 2.34B (2033) at 7.0%; and Market Research Future at USD 1.37B (2024) to USD 2.95B (2035) at 7.2%^14151617.

The directional agreement is the point — and within it, the endovenous-ablation sub-segment is consistently the single fastest-growing slice. Market Research Future puts the endovenous-ablation sub-segment at 7.40% and DelveInsight at 7.87%, both above their parent-market CAGRs; Mordor Intelligence pegs ablation growth at 6.87%¹⁸¹⁴¹⁹. Drilling into the endovenous-laser segment specifically, Future Market Insights sizes it at USD 0.5B (2025) to USD 1.1B (2035) at 7.9%, Data Bridge at USD 422M (2022) to USD 841M (2030) at 9.0%, and Coherent at USD 538M (2026) to USD 904M (2033) at 7.7%²⁰²¹²². North America is consistently the largest region (≈46%–48% share), with APAC the fastest-growing — up to 8.4% CAGR²³ — a relevant tailwind for an Asia-based, export-oriented manufacturer.

Forecasts are third-party publisher estimates, not facts. The value is the convergence on direction and growth band, not any single number.

Act II — The clinical shift from surgery to endovenous ablation

Takeaway: open stripping is effectively gone and minimally-invasive endovenous treatment has won — but inside US Medicare the modality war among ablation techniques is live, and thermal laser is losing share.

This is the data-original core of the report. It draws on a VEMERIX/Medison analysis of CMS Medicare Part B fee-for-service procedure volumes, 2013–2024 (national, facility plus office summed). One scope limit must be stated up front: CMS data covers Medicare fee-for-service only — an older US population. It understates the younger commercial and global EVLA market, and may overstate the pace of the surgery decline. Read it as a directional, high-fidelity window into the US shift, not the global picture.

Open surgery has collapsed

The structural shift is unambiguous. In US Medicare fee-for-service, open vein surgery's share of venous services fell from 10.3% in 2013 to 4.5% in 2024³. In absolute terms, open vein surgery and stripping fell from 33,742 to 18,723 services (−45%), and Medicare dollars paid against it dropped from USD 13.2M to USD 4.5M (−66%)³.

Drill into the codes and classic open stripping has essentially vanished. Complete stripping (CPT 37735) went from 100 services in 2013 to zero or suppressed from 2018 onward; ligation plus stripping (37722) fell 71% (938 to 271); and ligation alone (37700) fell 60% (982 to 392)³. The sizeable volume still coded as "surgery" is largely stab phlebectomy (37765/37766) — an adjunct performed alongside ablation, not classic stripping. True open-stripping codes are now in the low hundreds. As one peer-reviewed synthesis put it, "over the past two decades, minimally invasive endovenous therapies have largely supplanted open surgery"²⁵.

Inside minimally-invasive care, the modality war is live

Here is the nuance the data demands. The surgery-to-minimally-invasive shift is complete and durable. The modality-mix contest, however, is ongoing — and within Medicare, thermal laser is losing.

Endovenous ablation overall was roughly flat in volume (179,455 to 180,945 services, +1% over 2013–2024), but its share of venous services fell from 54.6% to 43.5% as other modalities grew faster³. Breaking ablation apart:

• Thermal laser (CPT 36478/79) peaked, then fell — from 89,191 services in 2013 to a 2016 peak of 95,015, then down to 35,884 by 2024 (the 36478+36479 code group), roughly −60% from peak³.
• Radiofrequency (36475/76) held flat — 90,264 to 89,929 services as a code group — making RF the larger thermal modality in Medicare (89,929 RF-group services versus 35,884 laser-group). Lead code 36475 alone billed 86,009 services to 47,580 beneficiaries for USD 67.5M in 2024³.
• Non-thermal microfoam (Varithena, 36482/83) is the disruptor — from zero before 2018 to 53,705 services / 26,269 beneficiaries / ~USD 65.0M paid by 2024. That single product now rivals RF's lead-code total (USD 67.5M) and dwarfs thermal laser's own ~USD 22.5M — though it remains short of the ~USD 90M+ paid across all thermal codes combined³.
• Sclerotherapy boomed — 115,654 to 215,976 services (+87%), with Medicare dollars up from USD 15.2M to USD 134.9M (+789%); it overtook ablation as the #1 venous service by volume in 2023–24³.

The critical interpretation: laser's Medicare decline reflects a non-thermal microfoam entrant eroding share, not a return to surgery. The minimally-invasive paradigm won; within it, payers and physicians are sorting modalities by anatomy, convenience and reimbursement. For a fiber maker, this is a reminder that the consumable thesis rests on the global, all-payer, younger EVLA market — not on the assumption that thermal laser auto-wins any single payer mix.

Modality trade-offs: each technique owns a clinical niche

Why does no single modality sweep the field? Because each occupies a defensible clinical niche, and thermal ablation retains a durability moat. The evidence:

• EVLA ≈ RFA on occlusion. A meta-analysis of 10 reports found a pooled relative risk of 1.01 (95% CI 0.95–1.07, I²=0%) — laser and radiofrequency are statistically equivalent on closure, and both match surgery²⁶.
• Thermal ablation beats foam on durable occlusion. A payer-policy synthesis put procedural success / 12-month occlusion at EVLA 95% / 89%, RFA 91% / 77%, and ultrasound-guided sclerotherapy 58–70% / 83%²⁷. A 5-year GSV RCT (n=166) put durable occlusion at open surgery 96%, EVLA 89%, and foam just 51% (p<0.001) — foam is markedly inferior on durability²⁸.
• Non-thermal glue ranks first on early anatomic success but carries hypersensitivity risk. A network meta-analysis ranked anatomic success VenaSeal (cyanoacrylate) 1st, RFA 2nd, EVLA 3rd, surgery 4th, MOCA 5th, sclerotherapy 6th — though credible intervals are wide²⁷. VenaSeal cyanoacrylate carries hypersensitivity in 4–20% of cases, and Varithena polidocanol microfoam carries DVT in 8.6%²⁹.
• Thermal has a nerve-safety edge over surgery and a segmentation logic. EVLA produces significantly fewer nerve injuries than open surgery; thermal ablation is preferred for straight saphenous anatomy, while non-thermal non-tumescent options suit tortuous, superficial or extrafascial veins²⁶²⁹.

Globally aligned guidelines put endothermal ablation first-line

The clinical shift is not just practice drift — it is codified in the major guidelines, which converge. NICE CG168 (UK, published 24 July 2013, still current in 2026) is the clearest. Recommendation 1.3.2 orders treatment explicitly: for confirmed varicose veins with truncal reflux, (1) "Offer endothermal ablation"; (2) "If endothermal ablation is unsuitable, offer ultrasound-guided foam sclerotherapy"; (3) "If ultrasound-guided foam sclerotherapy is unsuitable, offer surgery" — ablation first, foam second, surgery last³¹. Recommendation 1.3.4 even demotes conservative care: "Do not offer compression hosiery to treat varicose veins unless interventional treatment is unsuitable"³¹.

The European and US guidelines align. The ESVS 2022 Clinical Practice Guidelines make thermal ablation the Class I first choice for great-saphenous incompetence over high ligation/stripping and over foam sclerotherapy, across 94 recommendations (23 new Class I)³². The SVS/AVF/AVLS 2022–23 US guidelines recommend endovenous ablation over high ligation and stripping at Grade 1 (strong), Evidence B, and even suggest against a mandatory 3-month compression trial before intervention — removing a barrier to procedural volume³³.

Clinical-trial momentum reinforces the direction. A scan of ClinicalTrials.gov found 496 relevant trials, with start-year buckets rising from 50 (≤2009) to 224 (2020–26) — roughly 4.5× — and industry-sponsored starts rising even faster, from 18 to 98 (~5.4×). Device is the #1 intervention type (150 trials), ahead of procedure (109) and drug (62), and device-trial counts grew nearly fivefold (4.8×, from 20 to 96) across the period³⁴.

Act III — The technology and regulatory landscape

Takeaway: higher laser wavelengths paired with radial fibers deliver equal occlusion with far less pain and bruising; the device economics are a razor-and-blade model in which consumables, not consoles, are the recurring annuity; and the regulatory pathway is mature and low-risk.

Why higher wavelengths hit the vein wall harder

Endovenous laser physics turns on which chromophore — light-absorbing target — the wavelength addresses. Lower "hemoglobin-specific" wavelengths (810/940/980/1064 nm) target blood; "water-specific" wavelengths above ~1000 nm (1320/1470/1940 nm) target water in the vein wall itself³⁵. Because the vein wall is mostly water, higher wavelengths couple their energy directly into the target tissue.

The numbers are steep. Water absorption in the vein wall is roughly 9× higher at 1470 nm than at 980 nm³⁶ (one in-vitro study put the in-water figure even higher, ~40×)³⁷, and 1940 nm is more than 200× higher than 980 nm³⁸. Higher absorption lets the operator deliver less energy: 980 nm typically runs ~12–14 W and ~80 J/cm; 1470 nm runs 8–12 W at a linear endovenous energy density (LEED) of 60–100 J/cm; 1940 nm runs just 4–6 W at 40–60 J/cm³⁹. Lower energy means less thermal diffusion to surrounding perivenous tissue and nerves — the mechanism behind the morbidity improvement. At 1470 nm, penetration depth is about 0.34 mm, acting on more than half the vein-wall thickness without damaging the adjacent nerve compartment⁴⁰.

1470 nm plus radial fibers: equal occlusion, far less pain and bruising — with an honest caveat

The clinical payoff is well-documented, but it must be framed precisely. The strongest pooled evidence — a 2024 meta-analysis of 11 studies and 3,061 patients — found higher-wavelength 1470 nm achieved superior occlusion (odds ratios 2.0–2.8) across truncal and GSV veins at early, one-year and medium-long follow-up, with less paresthesia (RR 0.51, 95% CI 0.34–0.77) and less pain (SMD −0.62)⁴¹. Earlier randomized data point the same way: Hirokawa's 2015 multicenter RCT found 100% occlusion in both 1470/radial and 980/bare arms at 12 weeks, but pain of 0% versus 25.0% and bruising of 7.0% versus 57.1% (both p<0.0001)³⁶; and a 48-month series (n=400) found recanalization of 8.3% (1470 nm) versus 15.9% (980 nm) (p=0.017)⁴².

Now the caveat. Most of these trials changed the fiber as well as the wavelength — pairing 1470 nm with a radial-emitting fiber against 980 nm with a bare tip. So the documented advantage is best described as a higher-wavelength-plus-radial-fiber advantage, not proof the wavelength alone wins. The evidence that isolates wavelength is more modest: Malskat's 2016 RCT (940 vs 1470 nm with the same tulip-tip fiber) found 1470 nm improved early post-operative pain but similar success and adverse-event rates⁴³, and some authorities argue fiber design (bare vs jacketed/radial) may contribute more to recovery than wavelength⁴⁴. The honest reading: 1470 nm is the established mainstream "gold-standard" tier, the radial fiber is itself a value lever, and 1940 nm is the emerging frontier — but the recovery benefit is a system property of wavelength and fiber together.

The razor-and-blade model: filings skew heavily to consumables

Here is the commercial heart of the report. Endovenous laser is a razor-and-blade business: a durable capital console, plus a sterile single-use consumable consumed every single procedure. The consumable per case is not just the fiber — it is a full bill of materials: single-use radial or bare fiber, an introducer kit (6/7 Fr sheath, dilator, guidewire, needle) and tumescence-pump tubing, all sterile single-use⁴⁰.

The clearest evidence that consumables drive volume comes from the regulatory record itself. Of 56 curated US EVLA/vein 510(k) clearances (1997–2025), 40 are single-use kits, fibers, sheaths or catheters versus just 11 consoles⁴. Every clearance went the predicate-based Substantially Equivalent route (36 Traditional, 20 Special); zero required PMA or Class III — a mature, low-barrier pathway⁴. Named consumable clearances (procedure kits, accessory vein-ablation kits, catheters) dominate the filing record, confirming the recurring-revenue structure.

Market analysts describe the same structure in revenue terms. One notes "the aftermarket for single-use laser fibers and disposables will remain a critical, high-margin revenue stream," with compatibility and lock-in central⁴⁵; another that laser platforms "command higher upfront system value, with recurring fiber sales supporting long-term revenue streams"²³. The installed-base scale is real: AngioDynamics' VenaCure EVLT cites more than 1.5 million procedures worldwide at a 98% closure rate (the company's own figures), on a compact 1470 nm console — an installed franchise pulling fiber through with every case⁴⁶.

One honest contradiction to flag: market reports disagree sharply on the system-versus-consumable revenue split. Future Market Insights puts endovenous laser systems at 54.3% of laser-market revenue (2025), while a separate market report (publisher unverified in our pull) puts systems as high as 92% by product (2024)²⁰. Treat the precise split as unsettled. Consoles clearly dominate reported revenue today; the fiber is the faster-growing recurring annuity. The directional thesis — recurring consumables as the durable, high-margin pull-through — holds regardless of which split is correct.

A mature, low-risk safety profile after ~30 years

Endovenous laser is not an emerging-risk technology; it is a mature installed base. A VEMERIX/Medison analysis of FDA MAUDE found 2,106 EVLA/vein adverse-event reports (1997–2026), of which 62.9% were device malfunctions, 33.8% injuries, and only 0.6% — 12 reports in ~30 years — involved death⁴⁷. Most patient-impact codes are benign ("no clinical signs/symptoms," "no consequences," "no known impact"), with clinically meaningful events (foreign body, burns, hemorrhage) at low frequency⁴⁷. (MAUDE reports are not adjudicated as device-caused, and counts track installed base, not incidence — frame the profile neutrally.) Recalls reinforce the picture: vein-specific recalls were dominated by manufacturing root causes — process control, sterility, packaging — not clinical failure⁴⁸. Adverse-event volume has settled into a mature plateau (150–187/year in 2015–17, ~90–124/year through 2025)⁴⁷.

A fragmented, under-consolidated IP landscape

The patent landscape suggests room for a focused single-use-fiber player. A VEMERIX/Medison analysis of USPTO filings found the clean EVLA/varicose treatment-device core is small — roughly 60 patents — and the broader peripheral-venous device field about 266 patents (2005–2026), with no recent US-filing explosion (~10–15/year lately)⁴⁹. Critically, about 48% of venous patents (127/266) have no recorded assignee — they are inventor-owned — pointing to a fragmented field where fiber and consumable IP is split across small, independent filers⁴⁹. (This is a US-only keyword pull, not global patent families, so it under-represents the large multinational players and should not be read as global competitive share.)

Regulatory pathways and the China-entry precedent

The US 510(k) record also establishes that 1470 nm is already a cleared US wavelength⁴⁷, and that Chinese device makers have begun clearing US 510(k)s in 2023–25 (Acotec, Zhejiang Curaway and Baoding Te'anzhou among them), alongside completed Chinese device RCTs⁴³⁴. A China-based export pathway into regulated markets has precedent. On the consumable side, EVLA kits are cited in the European context as Class IIa devices⁴⁰ — a moderate-risk classification consistent with a predicate-based, kit-and-fiber commercial model.

Act IV — Strategic implications

Takeaway: demand is durable and growing, the recurring consumable is the annuity, single-use device imports are outpacing capital equipment, and APAC is the fastest-growing region — but the consumable opportunity rests on global all-payer demand and fiber/wavelength differentiation, not on assuming laser auto-wins every market.

Demand is durable and growing — across every estimate

The growth case does not depend on any single forecaster. The device market grows ~6–8% CAGR, the laser segment ~7.4–9.0%, and endovenous ablation is the fastest-growing modality at 6.9–7.9% across publishers^14202318. The epidemiological tailwind — aging plus obesity, in an under-treated population — is structural, not cyclical. For a decision-maker, the base rate is favorable: this is a growing market, not a contested zero-sum one.

The consumable is the recurring annuity

The single clearest strategic conclusion is that value accrues to the recurring consumable, not the one-time console. Three independent lines of evidence converge: the FDA filing mix (40 consumables vs 11 consoles)⁴; explicit market-report language about "recurring fiber sales" and a "critical, high-margin aftermarket"⁴⁵²³; and the per-case consumable bill of materials that is consumed and re-purchased every procedure⁴⁰. A console is sold once and amortised over thousands of cases; the fiber, sheath and kit are sold every case. The annuity is the blade, not the razor.

Single-use device imports are outgrowing capital equipment

Global trade data offers a directional confirmation. In UN Comtrade HS-code import series (2014–2024), single-use device baskets grew faster than the laser-containing equipment basket: syringes (HS 901831) at 8.3% CAGR and needles/catheters (HS 901839) at 7.2%, versus 5.9% for the laser-equipment basket (HS 901850)⁵⁰. These baskets are far broader than EVLA, and our pull carries no country dimension — so this is a directional consumable-demand signal, not a fiber market size and not a claim about any country's trade position. But the direction is consistent with everything else: consumables are the faster-growing demand.

APAC growth and an established China-entry precedent

For an Asia-based, export-oriented manufacturer, two facts matter. First, APAC is the fastest-growing region at up to 8.4% CAGR²³ — demand is shifting toward the manufacturer's home region. Second, Chinese device makers have already cleared US 510(k)s in 2023–25 and completed Chinese device RCTs⁴³⁴ — the regulated-market export pathway is not theoretical. Combined with a fragmented, ~48%-unassigned IP field⁴⁹, the structural conditions favor a focused single-use-fiber entrant.

The honest strategic nuance

The opportunity must be framed honestly. Within mature US Medicare, the surgery-to-minimally-invasive shift is complete, but thermal laser is ceding share to radiofrequency and microfoam³. So the consumable opportunity rests on the global, all-payer, younger EVLA market — which CMS data does not capture — and on fiber and wavelength differentiation (the 1470 nm-plus-radial-fiber recovery advantage) rather than on an assumption that laser auto-wins every payer mix⁴¹⁴⁴. The winning posture is a differentiated consumable in a growing global market, not a bet on thermal laser displacing every competing modality.

Where VEMERIX sits

VEMERIX (Weihai Medison) is positioned precisely at the annuity. Its registered flagship is a single-use 1470 nm endovenous laser fiber (NMPA Lu Mech Reg. 20192010517, Class II), paired with a partner-supplied diode laser source and indicated for endovenous laser ablation of varicose veins — i.e., the recurring consumable, not the capital system. As a maker of the single-use fiber in the established mainstream wavelength tier, within a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care, VEMERIX is aligned with the durable demand signal this report documents: minimally-invasive endovenous treatment, growing globally, consumed one sterile fiber at a time.

Conclusion

The surgery-to-minimally-invasive shift is structural and won. Open stripping has collapsed in US Medicare (−45% in services, surgery's share down to 4.5%), and NICE, ESVS and SVS/AVF guidelines all place endothermal ablation first-line above surgery. This is the durable backbone of demand — and it is not reversing.

Demand is large, under-treated and compounding. With ~190M US adults carrying CVD and 40M+ with varicose veins, against a treated cohort an order of magnitude smaller, the market is a latent demand pool — and an aging, increasingly obese population (US obesity ~42%) makes it grow. Every forecaster agrees on direction: ~6–9% CAGR through the early 2030s, with ablation the fastest slice.

The value is in the consumable, not the console. The FDA record (40 consumable clearances vs 11 consoles), market-report language on recurring fiber revenue, and trade flows (single-use imports outpacing capital equipment) all point one way: the recurring single-use fiber and kit is the high-margin annuity. The razor is sold once; the blade is sold every case.

Win on differentiation in a global market, not on modality triumphalism. Inside US Medicare, thermal laser is ceding share to RF and microfoam — so the opportunity rests on global, all-payer demand and on fiber/wavelength differentiation (1470 nm + radial fiber: equal occlusion, far less pain and bruising), not on assuming laser wins everywhere.

Talk to us

VEMERIX (Weihai Medison) manufactures the single-use 1470 nm endovenous laser fiber at the center of this shift, within a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care. If you are a distributor, procurement team or OEM/private-label buyer evaluating the endovenous-ablation consumable opportunity, we would welcome a conversation about your market and your tender requirements. Contact the VEMERIX team to start.